Sales and Marketing

Showing 15 posts of 11528 posts found.

robin_washington

Gilead’s CFO and Executive Vice President to depart in 2020

May 1, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …
gsk_boronia_australia

GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus

April 30, 2019 Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma

GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …

The price of access: Can the NHS afford Orkambi?

April 29, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …
shutterstock_243110086

Sanofi and Lexicon’s Zynquista scores EU approval for type 1 diabetes patients

April 29, 2019 Sales and Marketing Lexicon, Sanofi, Type 1 diabetes, Zynquista, diabetes, pharma

The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific …

Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland

April 29, 2019 Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma

Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …
credit_-_daniel_leal-olivas-afp

AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer

April 29, 2019 Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …

India hits back at claims they are leading source of counterfeit drugs

April 29, 2019 Sales and Marketing

India has rejected claims that they, along with China, are the chief source of counterfeit medicines around the world. In …
opioid_pills

Opioids to be labelled with addiction warning in UK

April 29, 2019 Sales and Marketing

All opioid medicines sold in the UK will be labelled with a warning as to the potential for addiction, Health …
gilead-sciences

Gilead’s selonsertib crashes at Phase 3 in NASH

April 26, 2019 Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib

Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Aduro Biotech, Cancer, GSK, ICR, J&J, JJ, Novartis, Sandoz, pharma

The Institute for Cancer Research (ICR) called for new measures to increase the speed with which patients in the UK …
richard_saynor

Senior GSK exec Richard Saynor revealed as new Sandoz CEO

April 26, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
lilly_building_with_american_flag_web

Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure

April 26, 2019 Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma

Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
dw-anzcxqaqavhl

FDA approves Beximco’s generic version of MSD’s allergy drug Periactin

April 25, 2019 Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma

Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …

ICR calls for faster access to innovative cancer drugs

April 25, 2019 Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing

The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …

Interactions with the Agencies During Drug Development

April 25, 2019 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cambridge, NDA, drug development

 NDA would like to invite you to join  Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines …
The Gateway to Local Adoption Series

Latest content